Table 1 Demographic characteristics of the study participants
Primary analysis N = 73 | Secondary analysis N = 122 | |
|---|---|---|
Gender | ||
Male | 33 (42%) | 62 (51%) |
Female | 39 (53%) | 56 (46%) |
Admitting team | ||
Medical Oncology | 47 (64%) | 85 (70%) |
Radiation Oncology | 17 (23%) | 22 (18%) |
Palliative Care | 7 (10%) | 9 (7%) |
Admission indication | ||
Symptom management | 55 (75%) | 88 (72%) |
Tumour type | ||
Lung | 14 (19%) | 23 (20%) |
Gastric and other upper GI | 11 (15%) | 15 (12%) |
Breast | 10 (14%) | 14 (11.5%) |
Prostate | 3 (4%) | 13 (11%) |
Colon | 8 (11%) | 9 (7%) |
Other | 23 (31.5%) | 39 (32%) |
Tumour stage | ||
Stage I or II | 8 (11%) | 10 (8%) |
Stage III | 12 (16%) | 19 (15%) |
Stage IV | 50 (68.5%) | 85 (69.7%) |
Site of metastasis | ||
No documented metastasis | 20 (27%) | 32 (26%) |
Bone | 18 (25%) | 24 (20%) |
Liver | 10 (14%) | 13 (11%) |
Lung | 4 (5.5%) | 7 (6%) |
Brain | 3 (4%) | 9 (7%) |
Multiple sites | 12 (16%) | 25 (20.5%) |
Unknown/missing | 6 (8%) | 10 (8%) |
ECOG Score | ||
1 or less | 22 (30%) | 31 (25%) |
2 | 22 (30%) | 40 (33%) |
3 or more | 19 (26%) | 34 (28%) |
Unknown/missing | 10 (14%) | 17 (14%) |
SQiD informant cohabitation with patient | 41 (56%) | 69 (57%) |
Median (IQR) | Median (IQR) | |
Age | 68 (60.5–78) | 68 (56–77.5) |
Australia-Modified Karnofsky Score | 70 (50–80) | 70 (50–70) |